GLP's ⏱ Half-life: ~48 minutes FDA-Approved

Pramlintide

Pramlintide Acetate (Symlin)

Updated March 30, 2026

Evidence at a Glance

Regulatory statusFDA-Approved
Symlin (amylin analog); FDA-approved 2005 as mealtime-insulin adjunct in T1D/T2D
Human evidenceExtensive
Animal evidenceExtensive

Pramlintide (Symlin) is a synthetic amylin analog FDA-approved in 2005 as an adjunct to mealtime insulin for type 1 and type 2 diabetes, supported by extensive controlled human trials.

What the research does not support

  • It is approved only as an adjunct to mealtime insulin, not as a standalone diabetes therapy or a general weight-loss drug.
  • Its effect on A1C is modest (roughly 0.2-0.7%) and its associated weight loss is small (up to ~1.6 kg).
  • It is not a GLP-1 agonist; amylin and GLP-1 are different pathways despite both affecting appetite and glucose.
  • Nausea is common and it carries a boxed warning for severe insulin-induced hypoglycemia when combined with insulin.
Half-Life
~48 minutes
Purity
Pharmaceutical grade
Mol. Weight
3,949.4 Da
Form
Solution in pre-filled pen

What is Pramlintide?

Pramlintide (Symlin) is the only FDA-approved amylin analog, used as an adjunct to mealtime insulin in both type 1 and type 2 diabetes. While it preceded the GLP-1 RA era and is less widely prescribed today, it remains an important therapeutic option and the foundation for next-generation amylin analogs like cagrilintide.

Dosage Information (Research Use)

T2D: 60mcg SC before major meals, may increase to 120mcg. T1D: 15mcg before meals, titrate to 60mcg. Must reduce mealtime insulin by 50% when starting. Prescription medication.

Reconstitution & Handling

Pre-filled pen — no reconstitution.

Half-Life & Pharmacokinetics

~48 minutes

Reported Observations in Literature

Nausea (28-48%, dose-dependent and usually transient), anorexia, vomiting, headache. Risk of severe hypoglycemia if mealtime insulin is not reduced. Injection site reactions.

Key Research References

  • Whitehouse F et al. “A randomized study and open-label extension evaluating the long-term efficacy of pramlintide.” Diabetes Care. 2002;25:724-30

How Pramlintide Works

Pramlintide is a synthetic analog of human amylin, a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. In diabetes, amylin secretion is deficient alongside insulin. Pramlintide restores amylin signaling — slowing gastric emptying, suppressing postprandial glucagon, and enhancing satiety. Unlike GLP-1 RAs, it works through calcitonin receptor/RAMP complexes.

Research Applications

🔬 Type 1 diabetes as adjunct to insulin
🔬 Type 2 diabetes with mealtime insulin
🔬 Postprandial hyperglycemia management

Research Findings

Clinical trials showed HbA1c reductions of 0.3-0.6% and weight loss of 1-2kg in both T1D and T2D. Reduces postprandial glucose excursions by ~50%. FDA-approved since 2005 but underused clinically.

Dosage & Administration

T2D: 60mcg SC before major meals, may increase to 120mcg. T1D: 15mcg before meals, titrate to 60mcg. Must reduce mealtime insulin by 50% when starting. Prescription medication.

Safety & Side Effects

Nausea (28-48%, dose-dependent and usually transient), anorexia, vomiting, headache. Risk of severe hypoglycemia if mealtime insulin is not reduced. Injection site reactions.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight 3,949.4 Da
Half-Life ~48 minutes
Purity Pharmaceutical grade
Form Solution in pre-filled pen
Storage Refrigerate 2-8°C. After first use, may store at room temperature up to 30 days.

Key Research References

  • Whitehouse F et al. "A randomized study and open-label extension evaluating the long-term efficacy of pramlintide." Diabetes Care. 2002;25:724-30

Related Peptides

View all →
CagriSema
GLP's
Fixed-dose combination of amylin analog cagrilintide with semaglutide for enhanced weight management research.
View Profile →
Tirzepatide
GLP's
First-in-class dual GIP/GLP-1 receptor agonist researched for superior metabolic outcomes compared to selective GLP-1 agonists.
View Profile → Buy Now
Exenatide
GLP's
First GLP-1 receptor agonist approved for diabetes, derived from Gila monster venom, available in twice-daily and once-weekly formulations.
View Profile →